Myeloid and Monocytic Leukemia | Pediatrics, Phase III
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
Volunteers
Health Professionals
What is the purpose of this trial?
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anna Sowa, MD
- Aron Flagg, MD
- Asher Marks, MD
- Ashley Bowers
- Claudia Auerbach, APRN
- Farzana Pashankar, MD, MRCP, MBBS
- Jeffrey Agli, APRN
- Juan Vasquez, MD
- Kate Hallissey
- Lakshmanan Krishnamurti, MD
- Mary Jane Hogan, MD, MPH, FAAP
- Michaela Russell
- Nitya Bakshi, MBBS, MS
- Prasanna Ananth, MD, MPH
- Rozalyn Levine Rodwin, MD, MHS
- Stephanie Prozora, MD
- Vidya Puthenpura, MD, MHS, FAAP
- Last Updated12/05/2024
- Study HIC#2000034938